TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

GlobeNewswire Inc. Logo GlobeNewswire Inc. By David-Alexandre C. Gros, M.D.
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Eledon Pharmaceuticals reported positive Phase 2 BESTOW trial results for tegoprubart, demonstrating favorable safety in kidney transplant prevention, and raised $57.5 million in financing to advance transplantation programs.

Insights
TpC   neutral

Used as a comparative benchmark for Verizon's valuation metrics


ELDN   positive

Demonstrated promising clinical trial results, reduced toxicities in transplant therapy, secured significant financing, and planned advancement to Phase 3 development